New drug duo shows promise in shrinking lung tumors before surgery
NCT ID NCT07329322
First seen Jan 10, 2026 · Last updated May 24, 2026 · Updated 19 times
Summary
This study tests whether a new drug, sacituzumab tirumotecan, given alone or with another drug (osimertinib), can shrink tumors before surgery in people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer). About 60 adults with early-stage, operable cancer will receive the treatment and then have surgery. The main goal is to see how many patients have very few or no cancer cells left in the removed tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.